LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
13
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In YRC Worldwide Inc. To Contact The Firm

NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in YRC Worldwide Inc. ("YRC" or the "Company")(NASDAQ: YRCW ) of the March 4, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in YRC stock or options between March 10, 2014 and December 14, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/YRCW . There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to   rgonnello@faruqilaw.com .

CONTACT: FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Attn:  Richard Gonnello, Esq. rgonnello@faruqilaw.com   Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Northern District of New York on behalf of all those who purchased YRC securities between March 10, 2014 and December 14, 2018 (the "Class Period"). The case, Lewis v. YRC Worldwide Inc. et al. , No. 19-cv-00001 was filed on January 2, 2019, and has been assigned to Judge David N. Hurd.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) from 2005 to at least 2013, YRC’s units systematically overcharged the federal government for freight carrier services; (2) this alleged misconduct caused the Department of Defense to overpay by millions of dollars for shipments that were lighter, and thus cheaper, than the weights for which the government was charged; (3) consequently, this alleged misconduct would subject YRC to enhanced government scrutiny and liabilities, including potentially owing treble damages under the False Claims Act; and (4) as a result, YRC’s public statements were materially false and misleading at all relevant times.

On December 14, 2018, the Department of Justice issued a press release stating that it had filed a complaint against YRC Worldwide entities for "systematically overcharg[ing] the government for freight carrier services and ma[king] false statements to the government that hid their misconduct[.]"

On this news, YRC's share price fell from $4.43 per share on December 13, 2018 to a closing price of $3.17 on December 14, 2018: a $1.26 or a 28.44% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding YRC's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Nippon Steel and TIER IV Unite for Autonomous Steel Transport

Updated Category News Views 357

Innovative Partnership for Autonomous Steel Transportation Nippon Steel Corporation, known as Japan's largest steel manufacturer, has initiated a significant collaboration with TIER IV, Inc., a trailblazer in the development of open-source software for autonomous driving. This partnership is set to revolutionize the way steel is transported within manufacturing...

Continue Reading
Brock Group Expands Leadership with New Regional Units

Updated Category News Views 303

The Brock Group Expands Leadership with New Regional Units The Brock Group is taking significant strides in enhancing its Brock Industrial Services (BIS) division. Recently, the company announced the creation of two new regional operating units designed to bolster its service capabilities and responsiveness for customers nationwide. Under this new organizational...

Continue Reading
Exploring Demand for Nasdaq-100 Index in Retirement Plans

Updated Category News Views 178

Rising Interest in Nasdaq-100 Index for Retirement Investments Recent findings reveal a burgeoning interest in the Nasdaq-100 Index among retirement plan participants. This trend signifies a noteworthy opportunity for retirement investment options catering to the needs of a modern workforce. A recent survey indicated that nearly 80 percent of 401(k) plan participants...

Continue Reading
ModivCare Securities Lawsuit Update: Key Details for Investors

Updated Category News Views 132

Important Updates Regarding ModivCare Lawsuit Levi & Korsinsky, LLP is reaching out to investors who have been part of ModivCare Inc. (NASDAQ: MODV) regarding a pivotal class action securities lawsuit. This notification signals a chance for investors affected by the Company’s alleged securities fraud to seek compensation. Understanding the Class Action Lawsuit The...

Continue Reading
Key Details for Nordic Fibreboard AS Annual Meeting Announcement

Updated Category News Views 163

Essential Details for the Upcoming Annual General Meeting The Annual General Meeting (AGM) of Nordic Fibreboard AS (registry code: 11421437) will be convened to discuss pivotal matters affecting the company's future. Set to take place at the headquarters in Pärnu, Estonia, the AGM is a prime opportunity for shareholders to engage directly with the company's management...

Continue Reading